Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU

• DOI: 10.1111/apt.70172
• Publication Date: 2025-05-02T12:26:20Z
• Authors: María José Casanova; Cristina Rubín de...; Sabino Riestra; Alfredo J. Lucendo; José Manuel Benítez; Mercè Navarro‐Llavat; Jesús Barrio; Víctor J. Morales...; Montserrat Rivero; David Busquets; Eduardo Leo‐Carne...; Oscar Nantes‐Cast...; Pablo Navarro; Manuel Van Domselaar; Ana Gutiérrez‐Casbas; Inmaculada Alonso...; Manuel Barreiro‐d...; Luis Fernández‐Sa...; Marisa Iborra; María Dolores Mar...; Natalia García‐Mo...; Jordi Guardiola; Abdel Bouhmidi‐As...; María Esteve; Carmen Muñoz‐Vill...; Iago Rodríguez‐Lago; Daniel Ceballos; Iván Guerra; Miriam Mañosa; Ignacio Marín‐Jim...; Isabel Vera‐Mendoza; Ana Garre; María Chaparro; Javier P. Gisbert
• Keywords: Cumulative incidence

ABSTRACT Background The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients who withdrew anti‐TNF therapy [withdrawal arm (WA)] and those maintained treatment [maintenance (MA)]. Aims To compare the long‐term risk of relapse these groups assess response to resumption. Methods This was a follow‐up extension trial. We analysed outcomes clinical from start EXIT. Results included 125 (63 MA 62 WA). Median for 26 WA. cumulative incidence (95% CI) 35% (23%–48%) 47% (34%–60%) WA; p = 0.3. In MA, relapses occurred 8% by 24 months. WA, 16% 39% rate per patient‐year 22% 19% Baseline faecal calprotectin > 250 μg/g only variable associated with higher relapse. Of 29 relapsed (90%) resumed therapy; these, 69% regained remission. Conclusion this extended analysis trial, withdrawing IBD not risk.